Catalyst Wire Dossier Catalyst Wire Dossier

Trivalent recombinant influenza vaccine

Influenza vaccine, recombinant, trivalent · Sanofi Pasteur
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Trivalent recombinant influenza vaccine, covering 2026-04-07 to 2026-04-07. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire

See pricing